StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3077% above fair value
$266.17−4.39 (-1.62%)

Close on Nov 3, 2026Market cap $641.44BP/E 40.4Yield 1.93%

Johnson & Johnson EDURANT / rilpivirine by Quarter

EDURANT / rilpivirine — International operational growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson EDURANT / rilpivirine: 2.4% in Q3 2026, down 7.5 pts from a year earlier.

Latest, Q3 2026
2.4%
Period ended Sep 30, 2026
Change on a year earlier
-7.5 pts
9.9% in Q3 2025
History
36 quarters
Since Q4 2017
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

“|| Intl | 382 | 378 | 1.0 | 2.4 | (1.4)”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEDURANT / rilpivirine — International operational growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 20262.4%-7.5 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 2026-3.8%-20.5 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 20263.2%-11.5 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202511.1%+5.5 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 20259.9%-1.5 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202516.7%+3.7 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202514.7%-1.0 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 20245.6%+4.1 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 202411.4%-2.0 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 202413.0%-4.3 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202415.7%-3.0 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 20231.5%-37.7 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 202313.4%+3.6 ptsForm 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 202317.3%+22.7 ptsForm 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 202318.7%+8.2 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 202339.2%+42.5 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗

Cite this data

StockData. (2026). Johnson & Johnson EDURANT / rilpivirine (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-edurant-intl-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.

See a number that looks wrong?